HealthDay News — For patients without diabetes, the incidence of statin-associated type 2 diabetes is relatively low, according to research published in The American Journal of Cardiology.
Payal Kohli, MD, from Kaiser Permanente in Denver, and colleagues conducted a retrospective analysis of data from subjects without diabetes in the Treating to New Targets (TNT) and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trials to identify increased risk of statin-associated type 2 diabetes. Participants were subdivided into 4 groups: normal fasting glucose (NFG) and triglyceride ≤1.7 mmol/L; NFG and triglyceride >1.7 mmol/L; prediabetes and triglycerides ≤1.7 mmol/L; and prediabetes and triglycerides >1.7 mmol/L. Comparable groupings were created by substituting BMI values for triglyceride concentration (<27.0 and ≥27.0 kg/m²).
The researchers found that 8.2% of the total population developed incident type 2 diabetes. There was variation in type 2 diabetes event rates (statin or placebo), from a low of 2.8%/3.2% (NFG and triglycerides ≤1.7 mmol/L) to a high of 22.8%/7.6% (prediabetes and triglycerides >1.7 mmol/L); the values were intermediate for only elevated triglycerides >1.7 mmol/L (5.2%/4.3%) or only prediabetes (12.8%/7.6%). The differences were comparable with BMI values.
“These data suggest that the diabetogenic impact of statin treatment is relatively modest in general,” the researchers wrote.
Disclosures: Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which funded the TNT and SPARCL clinical trials.
- Kohli P, Knowles JW, Sarraju A, Waters DD, Reaven G. Metabolic markers to predict incident diabetes mellitus in statin-treated patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trials). Am J Cardiol. 2016;118(9):1275-1281.